Italy In Vitro Diagnostics (IVD) Quality Control Market Size, Share,Trends, Growth Analysis Report, 2030

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Italy In Vitro Diagnostics (IVD) Quality Control Market analysis

Part of: In Vitro Diagnostics (IVD) Quality Control Market (Global)

The Italy In Vitro Diagnostics (IVD) Quality Control Market was valued at $47.2 Million in 2025 and projected to reach to $61.5 Million by 2030, representing a compound annual growth rate of CAGR 5.4%. Italy's IVD Quality Control Market is positioned for steady growth, supported by increasing regulatory pressures from EU directives and national healthcare policies mandating enhanced laboratory quality standards.

Italy In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights

Italy's market growth is driven by increasing regulatory compliance requirements, rising demand for diagnostic accuracy, and investments in laboratory infrastructure across Italian healthcare facilities.
The Italian market reflects broader European trends toward standardized quality assurance protocols in clinical diagnostics. In Italy, the IVD quality control sector benefits from the country's advanced healthcare system and stringent European Union regulatory frameworks.
Between 2025 and 2030, Italy is expected to see steady adoption of automated quality control solutions and enhanced testing methodologies.
Italy's pharmaceutical and diagnostic manufacturers are increasingly prioritizing quality control investments to meet both domestic and international standards, supporting market expansion throughout the forecast period..

Key Market Statistics

CAGR (2025-2030) CAGR 5.4%
Market Size, 2025 ~USD 47.2 Million
Forecast, 2030 ~USD 61.5 Million
Country Italy

Italy In Vitro Diagnostics (IVD) Quality Control Market Overview

Market Size & Growth :

Italy's IVD Quality Control Market is valued at USD 47.2 million in 2025, with a projected CAGR of 5.4% through 2030, reaching USD 61.5 million by forecast end.

Regulatory Compliance Driver :

Stringent EU and Italian regulatory requirements for diagnostic accuracy and laboratory standards are propelling demand for advanced quality control solutions across Italian healthcare facilities.

Laboratory Infrastructure Investment :

Significant investments in modernizing Italian hospital and diagnostic laboratory infrastructure are creating opportunities for quality control technology adoption and upgrades.

Diagnostic Accuracy Focus :

Rising emphasis on diagnostic precision and patient safety in Italian healthcare systems is driving adoption of robust quality control measures and standardized testing protocols.

Italy In Vitro Diagnostics (IVD) Quality Control Market Dynamics

The Italian healthcare system's commitment to improving diagnostic accuracy and patient outcomes is accelerating investments in quality control infrastructure and technologies.
Healthcare providers and diagnostic laboratories across Italy are prioritizing compliance with stringent quality benchmarks, creating sustained demand for innovative QC solutions.
The market is expected to benefit from ongoing digitalization of laboratory operations and integration of advanced analytical technologies in Italian medical facilities..

Related Ecosystem

In Vitro Diagnostics

Top Technologies

Polymerase Chain Reaction (PCR)
Enzyme-Linked Immunosorbent Assay (ELISA)
Dna Microarrays
Assay Kits
Microarrays

Top Companies

ROCHE HOLDINGS AG
Thermo Fisher Scientific Inc.
Danaher Corporation
Abbott Laboratories
Biomerieux s.a.

Medical Devices

Top Technologies

Polymerase Chain Reaction (PCR)
Magnetic Resonance Imaging (MRI)
Disposable Autoinjectors
Pulse Oximeters
Blood Pressure Monitors

Top Companies

Medtronic plc
Abbott Laboratories
Stryker Corporation
Becton, Dickinson and Company
JOHNSON & JOHNSON

Key Takeaways

Italy's IVD Quality Control Market is valued at USD 47.2 million in 2025 and will reach USD 61.5 million by 2030.
Italy experiences a 5.4% CAGR, reflecting steady growth driven by regulatory compliance and diagnostic accuracy demands.
Italy's advanced healthcare infrastructure and EU regulatory frameworks support sustained market expansion through 2030.
Italy's diagnostic manufacturers are increasing quality control investments to meet domestic and international standards.

In Vitro Diagnostics (IVD) Quality Control Market Report Scope

Report Metric	Details
Base Year	2025
Fastest Growing Segment	MOLECULAR DIAGNOSTICS (Technology)
Forecast Period	2025�2030
Growth Rate	CAGR of 5.5% from 2025 to 2030
Largest Segment	QUALITY CONTROL PRODUCTS (Product & Service)
Market Size Base Year (Billions)	~USD 1.65 (2025)
Revenue Forecast (Billions)	~USD 2.15 (2030)
Segments Covered	Product & Service, Type, Technology, Manufacturer Type, End User

Italy In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation

5 segment dimensions are covered across the global market.

By Product & Service

Data Management Solutions
Quality Assurance Services
Quality Control Products

By Type

Independent Controls
Instrument-Specific Controls
Other Controls
Serum/Plasma-Based Controls
Urine-Based Controls
Whole Blood-Based Controls

By Technology

Clinical Chemistry
Coagulation & Hemostasis
Hematology
Immunoassays
Microbiology
Molecular Diagnostics
Other Technologies

By Manufacturer Type

Original Equipment Manufacturer Controls
Third-Party Controls

By End User

Academic & Research Institutes
Clinical Laboratories
Hospitals
Other End Users

Target Audience

IVD Equipment Manufacturers : Need Italy-specific market data to assess market size, growth potential, and regulatory requirements for launching or expanding quality control product lines in Italian healthcare.
Diagnostic Laboratory Operators : Require market insights to understand QC technology trends, compliance requirements, and investment opportunities to enhance laboratory capabilities and operational efficiency.
Healthcare System Administrators : Need market intelligence on QC solutions and infrastructure investment trends to make informed procurement decisions and budget allocations for Italian hospital networks.
Medical Device Distributors & Suppliers : Require Italy-focused market analysis to identify growth segments, customer needs, and competitive landscape for effective distribution strategy and sales planning.
Healthcare Consultants & Investors : Need comprehensive Italy market data to evaluate investment opportunities, assess market viability, and provide strategic recommendations to healthcare stakeholders.

Key Companies in the Italy In Vitro Diagnostics (IVD) Quality Control Market

Company	HQ	Ownership	Strongest segments
BIOMERIEUX S.A.	France	Public Company	Clinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers),
CEPHEID INC.	United States	Private Company	GeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS),
IMMUCOR, INC.	United States	Private Company	Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products,
DIASORIN	Italy	Public Company	Immunodiagnostics � Infectious and Gastrointestinal Diseases,Immunodiagnostics � Endocrinology and Metabolic Disorders,Oncology and Tumor Markers,
UNILABS	Switzerland	Private Company	Core laboratory testing,Medical imaging services,Pathology and centres of excellence,
BIO-RAD LABORATORIES, INC.	United States	Public Company	Clinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services,
THERMO FISHER SCIENTIFIC, INC.	United States	Public Company	Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
ABBOTT	United States	Public Company	Diagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula),
LGC LIMITED	South Korea	Public Company	Ethylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene,
SIEMENS HEALTHINEERS AG	Germany	Public Company	Imaging,Diagnostics,Varian (Oncology),
QUIDELORTHO CORPORATION	United States	Public Company	Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC),
DANAHER CORPORATION	United States	Public Company	Biotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables),
SYSMEX CORPORATION	Japan	Public Company	Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers,
BIO-TECHNE CORPORATION	United States	Public Company	Protein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays,
MICROBIX BIOSYSTEMS INC.	Canada	Public Company	Antigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium,
GRIFOLS, S.A.	Spain	Public Company	Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies,

BIOMERIEUX S.A.

bioM�rieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

CEPHEID INC.

Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.

IMMUCOR, INC.

Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.

DIASORIN

DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.

UNILABS

Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.

BIO-RAD LABORATORIES, INC.

Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.

THERMO FISHER SCIENTIFIC, INC.

Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

ABBOTT

Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.

LGC LIMITED

LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.

SIEMENS HEALTHINEERS AG

Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.

QUIDELORTHO CORPORATION

QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.

DANAHER CORPORATION

Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.

SYSMEX CORPORATION

Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.

BIO-TECHNE CORPORATION

Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.

MICROBIX BIOSYSTEMS INC.

Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.

GRIFOLS, S.A.

Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.

Reasons to Buy this Report

Italy-Specific Market Sizing : Obtain precise market valuation data for Italy's IVD QC sector with accurate 2025 baseline (USD 47.2M) and 2030 forecasts, enabling confident investment and expansion decisions.
Regulatory Landscape Intelligence : Understand Italy-specific EU and national regulatory requirements driving QC adoption, helping suppliers align products and strategies with local compliance mandates.
Growth Opportunity Identification : Identify high-potential segments within Italian healthcare infrastructure investments and laboratory modernization initiatives to target expansion and partnership opportunities.
Competitive Positioning : Benchmark your offerings against Italy's market dynamics and growth trajectory (5.4% CAGR) to develop targeted go-to-market strategies for Italian healthcare providers.
Strategic Planning & Forecasting : Leverage Italy-focused market projections through 2030 to inform long-term business planning, resource allocation, and revenue forecasting for Italian market operations.

Frequently asked questions

What is the current size of Italy's IVD Quality Control Market?

Italy's IVD Quality Control Market is estimated at USD 47.2 million in 2025.

What is the projected market size for Italy by 2030?

Italy's IVD Quality Control Market is projected to reach USD 61.5 million by 2030.

What is the CAGR for Italy's IVD Quality Control Market?

Italy's market is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2030.

What factors are driving growth in Italy's IVD Quality Control Market?

Growth in Italy is driven by increasing regulatory compliance requirements, rising demand for diagnostic accuracy, and investments in laboratory infrastructure across Italian healthcare facilities.

How do EU regulations impact Italy's IVD Quality Control Market?

Italy's stringent European Union regulatory frameworks mandate standardized quality assurance protocols, supporting steady adoption of quality control solutions among Italian diagnostic manufacturers and healthcare providers.

RESEARCH METHODOLOGY

The study involved major activities in estimating the current market size for the global IVD quality controls market.

Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.

The four steps involved in estimating the market size are as follows:

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

In Vitro Diagnostics (IVD) Quality Control Market

Note 1: Others include sales, marketing, and product managers.

Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.

Stakeholders

Senior Management
End Users
Finance/Procurement Department
R&D Department

Report Objectives

To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report

Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies